Clinical trials: Schizophrenia and Related Disorders
Schizophrenia, Schizo Affective Disorder
Transcranial Weak Current Stimulation Treatments for Working Memory Dysfunction in Schizophrenia
For the present study, Investigators will examine the efficacy of active prefrontal anodal tDCS versus placebo (sham) interventions to treat WM dysfunction in schizophrenia.
- Trial name
- NCT04637724
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- Israel
- Volunteers
- 33 people
- Sponsor
- Oded Meiron
Schizophreniform Disorders, Bipolar Disorder
REWRITALIZE Your Recovery - Evaluation of a Creative Writing Group Intervention
Health institutes call for psychosocial interventions and recovery-oriented approaches as supplement to pharmacological treatment for mental health disorders.
- Conditions
- Schizophreniform Disorders, Bipolar Disorder, Severe Depression, Ptsd
- Trial name
- REWR (NCT06251908)
- Testing
- Rewritalize, Standard mental health care
- Where
- 6 sites in Denmark
- Volunteers
- 300 people
- Sponsor
- Amager Hospital
Schizophrenia, Bipolar Disorder
A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder
The purposes of this study are to evaluate the effects of a potent metabolic enzyme inducer, carbamazepine, on the steady-state pharmacokinetics of orally administered paliperidone ER and to evaluate the safety and tolerability…
- Trial name
- NCT00892125
- Testing
- paliperidone ER; Carbamazepine
- Volunteers
- 64 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizophreniform Disorders
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
The purpose of this trial is to study the effect of adding the omega-3 fatty acid EPA and/or Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related psychoses.
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00419146
- Testing
- Ethyl-eicosapentaenoic acid (EPA), Vitamins E + C
- Where
- Norway
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University Hospital, Aker
Schizophrenia, Major Depressive Disorder
Clinical Registry of Patients Under Treatment With Atypical Antipsychotics
Antipsychotic drugs are characterized by blocking dopaminergic D2 receptors. They have been found to be effective and safe for the treatment of schizophrenia, bipolar disorders, depressive episodes associated with bipolar…
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Depressive Disorder, Parkinson's Disease With Hallucinations
- Trial name
- NCT02409823
- Testing
- Atypical Antipsychotics
- Volunteers
- 665 people
- Sponsor
- Pontifical Catholic University of Argentina
Cardio Vascular Disease, Metabolic Syndrome (MetS)
Norwegian Mental Illness Heart Health Study
Norwegian patients with severe mental illnesses (SMI), such as schizophrenia spectrum or bipolar disorder, lose on average 10 years of life compared to mentally healthy individuals. Much of this gap is due to heart disease.
- Conditions
- Cardio Vascular Disease, Metabolic Syndrome (MetS), Severe Mental Disorder, Schizophrenia and Schizophrenia Spectrum Psychosis
- Trial name
- NORMI-Heart (NCT07085923)
- Testing
- Lifestyle Intervention
- Where
- Norway
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Madeleine Elisabeth Angelsen
Schizophrenia
Relapse Prevention in First Episode Schizophrenia: a 5 Year Trial
Objective: to evaluate the effectiveness of specialised and sustained intervention with or without parent groups during the initial phase of schizophrenia or related disorders on relapse prevention Methods: A three conditions…
- Trial name
- NCT01936220
- Testing
- Continuity of specialized care, Parent groups combined with Continuity of Specialized care, Discontinuity of care, non specialised care
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Severe Mental Disorder, Schizophrenia
Prediction and Intervention Effect of Rehabilitation Status for Severe Mental Disorder Patients Based on Multimodal Analysis and AI Agents
Mental health issues represent a major public health and social problem that significantly impacts economic and social development.
- Conditions
- Severe Mental Disorder, Schizophrenia, Schizoaffective Disorder, Paranoid Psychosis
- Trial name
- NCT06904079
- Testing
- Gamified Digital Rehabilitation, Routine Care
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Shanghai Mental Health Center
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Psychotic Disorders, Bipolar Disorder
Partners in Wellness: Evaluation of a Pay for Performance Program for High-Utilizers of Mental Health Services
Healthcare systems in the United States (U.S.) have long faced the considerable challenge of managing budgetary pressures while at the same time helping people with serious mental illness and/or addiction.
- Conditions
- Psychotic Disorders, Bipolar Disorder, Substance Use Disorders
- Trial name
- NCT06053346
- Testing
- Pay For Performance (PFP), Usual Care (UC)
- Volunteers
- 652 people
- Sponsor
- Stanford University
Prescription
The Third Survey of Prescription Pattern of Psychotropic Drugs in China
The investigators aimed to examine the psychotropic prescription pattern in China.
- Trial name
- NCT01668810
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- Peking University
Second Generation Antipsychotic Induced Metabolic Adverse Effects
Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics
Schizophrenia and bipolar disorder are frequently associated with an elevated risk for obesity, metabolic syndrome, diabetes mellitus, dyslipidemia and other metabolic disturbances.
- Trial name
- NCT01811160
- Testing
- Melatonin
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Schizophrenia, Substance Abuse
Screening Protocol for Research Participants
The Screening Protocol is a system devised to evaluate potential research participants for National Institute on Drug Abuse/Maryland Psychiatric Research Center (NIDA/MPRC) studies.
- Conditions
- Schizophrenia, Substance Abuse, Cocaine Abuse, Tobacco Use Disorder
- Trial name
- ScreenProt (NCT01010620)
- Testing
- Various Screening psychiatric and medical assessments
- Where
- United States
- Volunteers
- 523 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Bipolar Disorder
Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment
Non-interventional, prospective study to validate Spanish version of TOOL questionnaire in patients with schizophrenia and bipolar disorder under antipsychotic treatment
- Trial name
- TOOL (NCT00692133)
- Where
- 32 sites in Spain
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting
The purpose of this study is to assess the efficacy and safety of adding topiramate as compared to placebo to the medications a patient with bipolar disorder is already taking (lithium or valproate) to see if adding topiramate…
- Trial name
- NCT00237289
- Testing
- topiramate
- Volunteers
- 287 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Severe Mental Disorder, Smoking Cessation
Tobacco Intensive Motivational and Estimate Risk
Randomized, open label, prospective study with a 12-month follow-up period. The primary objective evaluates the effectiveness of an intensive anti-smoking programme that informs patients of their individual risk of lung damages…
- Conditions
- Severe Mental Disorder, Smoking Cessation, COPD
- Trial name
- NCT03583203
- Testing
- personalized information about lung damage
- Where
- Spain
- Volunteers
- 230 people
- Sponsor
- Hospital Universitario Reina Sofia de Cordoba
Schizophrenia, Schizoaffective Disorder
Factors Association With Poor Physical Function in Older Adults With Schizophrenia
Older adults with schizophrenia are a growing segment of the population yet their physical health status is poor. In order to design effective interventions, the contributing factors must be understood.
- Trial name
- NCT01092598
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of California, San Francisco
Cannabis Use
Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Background: Individuals with schizophrenia or schizoaffective disorders have a high prevalence of cannabis use. Understanding some of the environmental factors that maintain cannabis use, such as socially triggered cravings, is a…
- Trial name
- NCT01212081
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia, Schizoaffective
Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)
This is a 15 week trial to determine (1) the safety and tolerability of varenicline when used for smoking cessation/reduction in individuals with schizophrenia; (2) if treatment with varenicline affects the symptoms of…
- Conditions
- Schizophrenia, Schizoaffective, Psychosis
- Trial name
- NCT00702793
- Testing
- Varenicline
- Sponsor
- University of British Columbia
Psychotic Disorders, Stress Disorders, Traumatic
Psychotherapy for Psychosis, Adverse Events, and Substance Misuse
People with psychosis have significantly higher rates of adversity (e.g., abuse) and substance misuse (i.e., problematic drug and alcohol use) than people with other mental illnesses.
- Conditions
- Psychotic Disorders, Stress Disorders, Traumatic, Substance Use
- Trial name
- NCT04546178
- Testing
- Prolonged exposure (PE)+ therapy, Treatment as usual (TAU)
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Nova Scotia Health Authority